Learn more about Tiziana Tiziana Investor Deck Scientific Presentations and Updates
01 August 2022
New York, August 1, 2022 – Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”),...
Read more18 July 2022
New York, July 18, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has appointed Matthew Davis, MD, RPh as its...
Read more15 July 2022
New York, July 15, 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that the Board of Directors has accepted the voluntary resignation...
Read moreOur mission is to bring breakthrough therapies to patients with the aim of treating SPMS, Crohn's Disease, lung diseases and optimizing health outcomes.
Learn moreOur major clinical assets are supported by extensive worldwide issued patents and pending patent applications covering composition of matter, formulation technologies, manufacturing processes and disease indications.
Foralumab is a fully human anti-CD3 monoclonal antibody (mAb) for treatment of Crohn’ s Disease and neurodegenerative indications.
Learn more about ForalumabWe are developing a fully human monoclonal antibody (mAb) targeting the receptor for IL-6 as a potential treatment for lung diseases.
Learn more about Anti IL-6RMilciclib is the Company’s Phase 2 clinical candidate for the treatment in cancer indications. The company is exploring the combination of milciclib and gemcitibine in NSCLC patients with pan KRAS+ mutations.
Learn more about MilciclibTiziana is currently conducting clinical development programs for Foralumab, Anti IL-6R and Milciclib
Tiziana reported positive clinical data in a Phase I clinical trial of nasally-dosed Foralumab in healthy subjects in collaboration with Dr. Howard Weiner at Brigham and Women’s Hospital in Boston. Phase 1 patient enrollment is expected to begin in 3Q 2022 for orally administered Foralumab for the treatment of Crohn's disease. Phase 2 patient enrollment is expected to begin in 3Q 2022 for nasally administered Foralumab for the treatment of Pro-MS.
See more Foralumab clinical trialsManufacturing of clinical supplies for a Phase 1 study is anticipated to be completed in 3Q/4Q 2022. We anticipate filing a Australian TGA in 1Q 2023.
We are exploring a study to evaluate the combination of milciclib and gemcitabine in NSCLC subjects with associated pan KRAS-positive mutations. We expect to file an IND in 3Q 2022.
See more Milciclib clinical trials
